Serum Life Sciences to invest £50m in Oxford Biomedica
Serum Life Sciences, a unit of India-based Serum Institute of India (SII), is set to invest more than £50m in UK-based Oxford Biomedica, a gene and cell therapy
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XSerum Life Sciences, a unit of India-based Serum Institute of India (SII), is set to invest more than £50m in UK-based Oxford Biomedica, a gene and cell therapy
Novartis has acquired Arctos Medical, a Swiss gene therapy start-up developing optogenetic therapies for the treatment of blindness, for an undisclosed amount. The acquisition adds a pre-clinical optogenetics-based
Samsung Bioepis and Biogen have received the US Food and Drug Administration (FDA) approval for Byooviz (ranibizumab-nuna), a biosimilar to Roche’s Lucentis (ranibizumab). Byooviz is indicated for neovascular
Pfizer and BioNTech unveiled top-line results from a Phase 2/3 trial, in which their Covid-19 vaccine Comirnaty elicited superior immune responses in children aged five to 11 years,
The US Food and Drug Administration (FDA)’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has recommended the Emergency Use Authorization (EUA) for a booster dose of Pfizer
Celltrion has received full approval from the Korean Ministry of Food and Drug Safety (MFDS) for its a monoclonal antibody treatment regdanvimab (CT-P59) to treat Covid-19. The therapy
Biocon Biologics Limited (BBL), a subsidiary of Biocon, has agreed to offer approximately 15% stake to Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute
Health Canada has approved Moderna’s New Drug Submission (NDS-CV) for its mRNA-based Covid-19 vaccine, dubbed Spikevax (elasomeran). The regulatory approval allows for immunisation of Spikevax, previously called Moderna
Takeda has obtained the US Food and Drug Administration (FDA) approval for Exkivity (mobocertinib) to treat a type of non-small cell lung cancer (NSCLC). The drug was indicated
Regeneron Pharmaceuticals announced that the US government has agreed to purchase additional doses of its Covid-19 antibody cocktail REGEN-COV. The agreement with the Department of Health and Human